Cosmos Pharmaceutical achieved sales of \u00a51,009.9 billion (up 8.7% YoY) and operating profit of \u00a54.253 billion (up 4.8%) for the fiscal year ending May 2026. The company expanded its store network and closed some stores, increasing net assets to \u00a5283.7 billion. It also signals continued store expansion and steady performance in the upcoming period.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3349","jir_company_name":"Cosmos Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/3349-20260713-01.pdf","jir_short_summary":"Cosmos Pharmaceutical achieved sales of \u00a51,009.9 billion (up 8.7% YoY) and operating profit of \u00a54.253 billion (up 4.8%) for the fiscal year ending May 2026. The company expanded its store network and closed some stores, increasing net assets to \u00a5283.7 billion. It also signals continued store expansion and steady performance in the upcoming period.","jir_summary":"### Performance Overview\nFor the fiscal year ending May 2026, Cosmos Pharmaceutical reported sales of \u00a51,009.9 billion, operating profit of \u00a54.253 billion, and net income of \u00a53.046 billion, all showing increases compared to the previous corresponding period. Store openings resulting from active expansion policies increased the total number of stores to 1,708, strengthening regional presence. Financially, net assets grew to \u00a5283.7 billion, maintaining a stable financial foundation.\n\n### Outlook and Impact on Shareholders\nFor the next fiscal year (ending May 2027), sales are forecasted at \u00a51,190.0 billion, with net income of \u00a53.07 billion. The company will continue expanding its store network and promoting low-price sales. An annual dividend of \u00a584 is planned, continuing shareholder returns. Through proactive store expansion and prudent management, Cosmos Pharmaceutical maintains an attractive growth platform for investors.","jir_financial_highlights":"Sales: \u00a51,009.9 billion (YoY 8.7% increase)\nOperating Profit: \u00a54.253 billion (YoY 4.8% increase)\nNet Income Attributable to Owners of Parent: \u00a53.046 billion (YoY 3.4% increase)","jir_category":"","jir_hashtags":"#CosmosPharmaceutical, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Sales: \u00a51,009.9 billion (YoY 8.7% increase)\nNet Assets: \u00a5283.7 billion (up 10.2% compared to previous period)\nNumber of Stores: 1,708 stores (105 new stores opened, 6 stores closed)","jir_meta_title":"\u3010Cosmos Pharmaceutical\u30112026 Financial Results | Sales of \u00a51,009.9 billion (YoY 8.7% increase)","jir_meta_description":"Cosmos Pharmaceutical achieved sales of \u00a51,009.9 billion and net income of \u00a53.206 billion for the fiscal year ending May 2026, with plans for store expansion and steady management going forward. Detailed report.","jir_og_title":"\u3010Cosmos Pharmaceutical\u30112026 Financial Results | Sales of \u00a51,009.9 billion (YoY 8.7% increase)","jir_og_description":"Cosmos Pharmaceutical's 2026 financial results show sales of \u00a51,009.9 billion and net income of \u00a53.206 billion. The company plans continued store expansion and dividend increases in the upcoming period.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7750,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-79885","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n